Morgan Stanley
DAWN

Morgan Stanley’s Day One Biopharmaceuticals DAWN Stock Holding History

Morgan Stanley’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Sell
687,107
-863,167
-56% -$12.2M ﹤0.01% 3230
2025
Q4 		$14.4M Buy
1,550,274
+246,245
+19% +$2.06M ﹤0.01% 3244
2025
Q3 		$9.19M Sell
1,304,029
-49,119
-4% -$338K ﹤0.01% 3620
2025
Q2 		$8.8M Buy
1,353,148
+643,733
+91% +$4.43M ﹤0.01% 3554
2025
Q1 		$5.63M Sell
709,415
-370,853
-34% -$4M ﹤0.01% 3834
2024
Q4 		$13.7M Buy
1,080,268
+305,757
+39% +$4.25M ﹤0.01% 3110
2024
Q3 		$10.8M Buy
774,511
+607,265
+363% +$8.66M ﹤0.01% 3366
2024
Q2 		$2.3M Sell
167,246
-65,304
-28% -$955K ﹤0.01% 4468
2024
Q1 		$3.84M Sell
232,550
-436,328
-65% -$6.53M ﹤0.01% 4123
2023
Q4 		$9.77M Buy
668,878
+510,432
+322% +$6.19M ﹤0.01% 3935
2023
Q3 		$1.94M Sell
158,446
-79,258
-33% -$1.03M ﹤0.01% 4413
2023
Q2 		$2.84M Buy
237,704
+53,785
+29% +$702K ﹤0.01% 4190
2023
Q1 		$2.46M Buy
183,919
+96,654
+111% +$1.89M ﹤0.01% 4322
2022
Q4 		$1.88M Sell
87,265
-20,140
-19% -$413K ﹤0.01% 4509
2022
Q3 		$2.15M Buy
107,405
+70,365
+190% +$1.5M ﹤0.01% 4376
2022
Q2 		$662K Buy
37,040
+20,587
+125% +$213K ﹤0.01% 5269
2022
Q1 		$162K Buy
16,453
+2,489
+18% +$32.9K ﹤0.01% 6034
2021
Q4 		$236K Buy
13,964
+10,997
+371% +$226K ﹤0.01% 5980
2021
Q3 		$70K Buy
2,967
+593
+25% +$14.2K ﹤0.01% 6560
2021
Q2 		$54K Buy
+2,374
New +$49.5K ﹤0.01% 6637

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Morgan Stanley's DAWN Position: Q1 2026 in Review

Morgan Stanley reduced its Day One Biopharmaceuticals (DAWN) stake by 56% in Q1 2026, selling an estimated $12.2M and leaving 687,107 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3230.

Morgan Stanley first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Morgan Stanley held 687,107 shares of Day One Biopharmaceuticals worth $14.7M as of Q1 2026.
  • Morgan Stanley sold 863,167 Day One Biopharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3230 holding.
  • Morgan Stanley first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.